Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
The results were published in an article, “Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice,” in the journal Neurology Clinical Practice.
Tysabri, marketed by Biogen, is an antibody treatment that blocks immune system cells from moving into the brain and spinal cord. It was approved by the U.S. Food and Drug Administration (FDA) as a treatment for MS in 2004, but was pulled from the market after being linked to a rare neurological disorder called progressive multifocal leukoencephalopathy (PML). Read on.